We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Rapid Urease Test Developed to Diagnose H. pylori Infection in Asymptomatic Patients

By LabMedica International staff writers
Posted on 25 Oct 2011
A new rapid urease assay offers high sensitivity and accuracy for diagnosis of Helicobacter pylori in untreated patients.

Dyspepsia is a multifaceted range of symptoms related to the upper gastrointestinal (GI) tract. More...
Population-based surveys have shown dyspepsia to be a global problem with 15% to 40% of the populace complaining of upper GI symptoms. Although several guidelines recommend an initial noninvasive “test and treat” approach for the diagnosis of H. pylori in primary care if patients do not complain of acute symptoms and are younger than 45-50 years, many dyspeptic patients are still referred for endoscopy.

In a recent cohort of US patients, about one-third of all upper endoscopic procedures were performed for patients with dyspeptic symptoms without alarm symptoms. In some countries, the high prevalence of gastric cancer in young dyspeptic patients also makes early endoscopy an important feature of dyspepsia management.

Endoscopic tests for H. pylori have progressed in the past 10 years and one area of growth has been the speed with which the rapid urease test (RUT) can be read. A new urease test, the Urea ultrafast-test--UFT 300, developed by ABS Advanced Biomedical Systems (Cernusco sul Naviglio, Italy) can be read in five minutes. The test, which was approved in the European Union, has the potential to simplify the clinical management further by allowing the result of the test to be included in the endoscopy report when patient leaves the endoscopy unit.

To assess the diagnostic accuracy of this new rapid urease test to diagnose H. pylori infection in untreated patients using an independent external reference standard, scientists from the department of internal medicine and gastroenterology at the University of Bologna (Italy) examined 1,000 consecutive dyspeptic patients and demonstrated that the new rapid urease UFT300 test offers high sensitivity (94.5%) and accuracy (100%), with a considerably shorter time period to read both a positive and a negative test.

The study was published January 2010 in the journal Alimentary Pharmacology & Therapeutics journal.

Related Links:
ABS Advanced Biomedical Systems
University of Bologna



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Specimen Radiography System
TrueView 200 Pro
New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: Brain biomarkers of Alzheimer\'s disease can be detected as early as middle age (Photo courtesy of University of Shutterstock)

Blood-Based Biomarkers Could Detect Alzheimer's as Early as Middle Age

As the global population ages, Alzheimer's disease and other dementing diseases are becoming more prevalent. The disease processes leading to Alzheimer's symptoms can begin years or even decades before... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: Micrograph showing the distribution of misfolded proteins in myeloma cells (Photo courtesy of Helmholtz Munich)

Novel Method Tracks Cancer Treatment in Cells Without Dyes or Labels

Multiple myeloma is a blood cancer that affects plasma cells in the bone marrow, leading to abnormal protein production, weakened immunity, and organ damage. Traditional methods for evaluating myeloma... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.